AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the busines...
AmpliPhi Biosciences (NYSEMKT: APHB ): Q1 GAAP EPS of -$0.11 in-line. More news on: AmpliPhi Biosciences Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company (to be named Armata Pharmaceuticals) focused on development of precisely targeted bacteriophage therapeutics $10.0 million of new capital to be invested in combined co...
AmpliPhi Biosciences (NYSEMKT: APHB ): Q4 GAAP EPS of -$0.15. More news on: AmpliPhi Biosciences Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmac...
News, Short Squeeze, Breakout and More Instantly...
AmpliPhi Biosciences Corporation Company Name:
APHB Stock Symbol:
NYSE Market:
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the busines...
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company (to be named Armata Pharmaceuticals) focused on development of precisely targeted bacteriophage therapeutics $10.0 million of new capital to be invested in combined co...
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmac...